SIGA TECHNOLOGIES INC
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Accelerated filer
State of Incorporation
DE
Business Address
31 EAST 62ND STREET, NEW YORK, NY, 10065
Mailing Address
31 EAST 62ND STREET, NEW YORK, NY, 10065
Phone
212-672-9100
Fiscal Year End
1231
EIN
133864870
Financial Overview
FY2025
$215.80M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 8-K Current report of material events | March 10, 2026 | View on SEC |
| 10-K Annual financial report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | January 28, 2026 | View on SEC |
| 8-K Current report of material events | November 6, 2025 | View on SEC |
Annual Reports
10-K
March 10, 2026
- TPOXX is the only FDA-approved oral antiviral for smallpox, securing a unique market position.
- Long-standing BARDA contract provides stable revenue visibility through at least 2025.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.